摘要
目的:了解2015~2018年杭州市乳腺癌患者蒽环类药物的使用现状及其用药特点和趋势。方法:对2015~2018年杭州市12家医院蒽环类药物的用药金额、用药频度(DDDs)、限定日费用(DDC)及药物利用指数(DUI)等指标进行统计分析。结果:2015~2018年乳腺癌患者蒽环类药物的销售总金额呈下降趋势,相比2015年,2018年销售金额下降52.6%;销售金额及用药频率最高的是表柔比星,其次是多柔比星脂质体,多柔比星的DDC、用药金额及DDDs均最低;4种蒽环类药物的DUI在0.80~1.06之间。结论:杭州市12家医院乳腺癌患者蒽环类药物的使用剂量基本合理,疗效较好、不良反应较低的蒽环类药物在临床使用中占优势。
Objective:To analysis the characteristic and tendency of anthracyclines used by breast cancer patients in Hangzhou. Methods:The prescriptions data of breast cancer patients in 12 hospitals of Hangzhou from 2015 to 2018 were statistically analyzed, including the consumption, frequency of utilization, defined daily cost and drug utilization index. Results:The consumption of anthracyclines showed an overall downward trend and decreased by 52.6% in 2018 compared to 2015. The top sales and frequency of utilization of anthracyclines were epirubicin, followed by doxorubicin liposomes;the defined daily cost, consumption and frequency of utilization of doxorubicin were the lowest;the drug utilization index of the four anthracycline drugs was between 0.80 and 1.06. Conclusion:The utilization of anthracyclines varieties used by breast cancer patients was generally reasonable in 12 hospitals of Hangzhou between 2015 and 2018. Anthracycline drugs with good curative effect and low adverse reactions were dominant in clinical use.
作者
方琦璐
李清林
陈凌亚
孔思思
孙娇
辛文秀
Fang Qilu;Li Qinglin;Chen Lingya;Kong Sisi;Sun Jiao;Xin Wenxiu(Institute of Cancer Research and Basic Medical Sciences of Chinese Academy of Sciences,Cancer Hospital of University of Chinese Academy of Sciences,Zhejiang Cancer Hospital,Hangzhou 310022,China)
出处
《药物流行病学杂志》
CAS
2020年第5期324-326,331,共4页
Chinese Journal of Pharmacoepidemiology
基金
国家自然科学基金项目(编号:81903898)
浙江省自然科学基金项目(编号:LQ18H160018)。
